KemPharm has appointed Nichol Ochsner VP, investor relations and corporate communications. In the newly created position, Ochsner will be responsible for relations with the company’s shareholders and prospective investors, as well as with the analysts who cover the company.

She was previously EVP, investor relations and corporate communications at Statera Biopharma. Before that, she held IR roles at TherapeuticsMD and Aralez Pharmaceuticals.